Fibroblast Growth Factor Receptor 2 Inhibitor Market
- 2026 年市場規模
- USD 196.3 Mn
- 2033 年預估規模
- USD 554.0 Mn
- 年複合成長率 CAGR
- 16%
以上數字由 Coherent Market Insights 於本報告中提出，量子訊息原樣引用。
授權報價
| Single User Price | $4,500 USD |
| Enterprise License | $10,000 USD |
完整報告名稱與涵蓋範圍
Fibroblast Growth Factor Receptor 2 Inhibitor Market, By Drug (Pemigatinib, Futibatinib, Tasurgratinib, Tinengotinib, and Lirafugratinib), By Indication (Cholangiocarcinoma, Gastric Cancer, Endometrial Cancer, and Others), By End User (Hospitals, Specialty Clinics, Cancer Centers, and Others), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)
報告摘要
The global fibroblast growth factor receptor 2 inhibitor market is estimated to be valued at USD 196.3 Mn in 2026 and is expected to reach USD 554.0 Mn by 2033, exhibiting a compound annual growth rate (CAGR) of 16.0% from 2026 to 2033. Fibroblast growth factor receptor 2 (FGFR2) inhibitors are targeted therapeutic drugs that are a part of a group of medications to halt unusual FGFR2 signaling through various factors including genetic fusions, mutations, and amplification in diseases such as gastric and uterine cancer, breast cancer, intrahepatic cholangiocarcinoma. This treatment strategy targeting signaling pathways that regulate proliferation, survival of cancer cells and angiogenesis has evolved as a crucial treatment regimen in the precision oncology sector.
The global fibroblast growth factor receptor 2 inhibitor market will gain momentum due to rising trends for cancer treatment focused on biomarkers, growing utilization of genome profiling technologies and heightened knowledge of FGFR2-based tumor biological processes. Moreover, the number of approvals and designations granted to specific FGFR inhibitors coupled with ongoing development of diagnostics paired along with companion tests has a capacity to identify eligible population for FGFR2-targeted drugs and aids market augmentation. FGFR2 inhibitor treatment also continues to gain traction across developed and developing markets.
Market Dynamics
The global fibroblast growth factor receptor 2 inhibitor market is driven by increasing incidences of FGFR2-altered cancers, especially cholangiocarcinoma. Moreover, the increasing prescription rates of genomic profiling and companion diagnostics to accurately determine the eligibility of patients for the utilization of FGFR2-targeted agents and regulatory approvals. Additionally, pipeline progress associated with the next-generation selective FGFR2 inhibitors are expected to play a critical role in propelling the market. Also, strategic partnerships among pharmaceutical organizations, biotechnology companies and research institutions will further strengthen the pace of the FGFR2 inhibitors pipeline.
However, a number of constraints are present in the market, such as prohibitively expensive nature of targeted therapies, lack of adequate reimbursement facilities across numerous regions, and limited patient pool affected by FGFR2 alterations.
Nevertheless, extensive pipeline progress focused on next-generation FGFR2 inhibitors, application of combinatorial therapy and increase in reach of molecular diagnostics in developing markets will offer new opportunities for growth in fibroblast growth factor receptor 2 inhibitor market.
Key Features of the Study
• This report provides in-depth analysis of the global fibroblast growth factor receptor 2 inhibitor market, and provides market size (USD Million) and compound annual growth rate (CAGR%) for the forecast period (2026–2033), considering 2025 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global fibroblast growth factor receptor 2 inhibitor market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Incyte Corporation, Taiho Pharmaceutical Co., Ltd., Relay Therapeutics, Inc., Janssen Pharmaceuticals, BridgeBio Pharma, Inc., Tyra Biosciences, Inc., Abbisko Therapeutics Co., Ltd., AstraZeneca PLC, Kinnate Biopharma Inc., and Novartis AG
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global fibroblast growth factor receptor 2 inhibitor market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global fibroblast growth factor receptor 2 inhibitor market
Market Segmentation
• Drug Insights (Revenue, USD Mn, 2021 - 2033)
o Pemigatinib
o Futibatinib
o Tasurgratinib
o Tinengotinib
o Lirafugratinib
• Indication Insights (Revenue, USD Mn, 2021 - 2033)
o Cholangiocarcinoma
o Gastric Cancer
o Endometrial Cancer
o Others
• End User Insights (Revenue, USD Mn, 2021 - 2033)
o Hospitals
o Specialty Clinics
o Cancer Centers
o Others
• Regional Insights (Revenue, USD Mn, 2021 - 2033)
o North America
U.S.
Canada
o Latin America
Brazil
Argentina
Mexico
Rest of Latin America
o Europe
Germany
U.K.
Spain
France
Italy
Russia
Rest of Europe
o Asia Pacific
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
o Middle East
GCC Countries
Israel
Rest of Middle East
o Africa
South Africa
North Africa
Central Africa
• Key Players Insights
o Incyte Corporation
o Taiho Pharmaceutical Co., Ltd.
o Relay Therapeutics, Inc.
o Janssen Pharmaceuticals
o BridgeBio Pharma, Inc.
o Tyra Biosciences, Inc.
o Abbisko Therapeutics Co., Ltd.
o AstraZeneca PLC
o Kinnate Biopharma Inc.
o Novartis AG
目錄 Table of Contents
Table of Contents
1. Research Objectives and Assumptions
o Research Objectives
o Assumptions
o Abbreviations
2. Market Purview
o Report Description
Market Definition and Scope
o Executive Summary
Global Fibroblast Growth Factor Receptor 2 Inhibitor Market, By Drug
Global Fibroblast Growth Factor Receptor 2 Inhibitor Market, By Indication
Global Fibroblast Growth Factor Receptor 2 Inhibitor Market, By End User
Global Fibroblast Growth Factor Receptor 2 Inhibitor Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
o Market Dynamics
o Impact Analysis
o Key Highlights
o Regulatory Scenario
o Product Launches/Approvals
o PEST Analysis
o PORTER’s Analysis
o Market Opportunities
o Regulatory Scenario
o Industry Trends
4. Global Fibroblast Growth Factor Receptor 2 Inhibitor Market, By Drug, 2021-2033, (USD Mn)
o Introduction
Market Share Analysis, 2026 and 2033 (%)
Y-o-Y Growth Analysis, 2022 - 2033
Segment Trends
o Pemigatinib
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
o Futibatinib
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
o Tasurgratinib
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
o Tinengotinib
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
o Lirafugratinib
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
5. Global Fibroblast Growth Factor Receptor 2 Inhibitor Market, By Indication, 2021-2033, (USD Mn)
o Introduction
Market Share Analysis, 2026 and 2033 (%)
Y-o-Y Growth Analysis, 2022 - 2033
Segment Trends
o Cholangiocarcinoma
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
o Gastric Cancer
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
o Endometrial Cancer
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
o Others
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
6. Global Fibroblast Growth Factor Receptor 2 Inhibitor Market, By End User, 2021-2033, (USD Mn)
o Introduction
Market Share Analysis, 2026 and 2033 (%)
Y-o-Y Growth Analysis, 2022 - 2033
Segment Trends
o Hospitals
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
o Specialty Clinics
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
o Cancer Centers
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
o Others
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
7. Global Fibroblast Growth Factor Receptor 2 Inhibitor Market, By Region, 2021 - 2033, Value (USD Mn)
o Introduction
Market Share (%) Analysis, 2026, 2029 & 2033, Value (USD Mn)
Market Y-o-Y Growth Analysis (%), 2022 - 2033, Value (USD Mn)
Regional Trends
o North America
Introduction
Market Size and Forecast, By Drug, 2021 - 2033, Value (USD Mn)
Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Mn)
Market Size and Forecast, By End User, 2021 - 2033, Value (USD Mn)
Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
o U.S.
o Canada
o Latin America
Introduction
Market Size and Forecast, By Drug, 2021 - 2033, Value (USD Mn)
Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Mn)
Market Size and Forecast, By End User, 2021 - 2033, Value (USD Mn)
Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
o Brazil
o Argentina
o Mexico
o Rest of Latin America
o Europe
Introduction
Market Size and Forecast, By Drug, 2021 - 2033, Value (USD Mn)
Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Mn)
Market Size and Forecast, By End User, 2021 - 2033, Value (USD Mn)
Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
o Germany
o U.K.
o Spain
o France
o Italy
o Russia
o Rest of Europe
o Asia Pacific
Introduction
Market Size and Forecast, By Drug, 2021 - 2033, Value (USD Mn)
Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Mn)
Market Size and Forecast, By End User, 2021 - 2033, Value (USD Mn)
Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
o China
o India
o Japan
o Australia
o South Korea
o ASEAN
o Rest of Asia Pacific
o Middle East
Introduction
Market Size and Forecast, By Drug, 2021 - 2033, Value (USD Mn)
Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Mn)
Market Size and Forecast, By End User, 2021 - 2033, Value (USD Mn)
Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
o GCC Countries
o Israel
o Rest of Middle East
o Africa
Introduction
Market Size and Forecast, By Drug, 2021 - 2033, Value (USD Mn)
Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Mn)
Market Size and Forecast, By End User, 2021 - 2033, Value (USD Mn)
Market Size and Forecast, By Country/Region, 2021 - 2033, Value (USD Mn)
o South Africa
o North Africa
o Central Africa
8. Competitive Landscape
o Incyte Corporation
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
o Taiho Pharmaceutical Co., Ltd.
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
o Relay Therapeutics, Inc.
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
o Janssen Pharmaceuticals
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
o BridgeBio Pharma, Inc.
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
o Tyra Biosciences, Inc.
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
o Abbisko Therapeutics Co., Ltd.
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
o AstraZeneca PLC
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
o Kinnate Biopharma Inc.
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
o Novartis AG
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
9. Analyst Recommendations
o Wheel of Fortune
o Analyst View
o Coherent Opportunity Map
10. References and Research Methodology
o References
o Research Methodology
o About us
Browse 32 market data tables and 28 figures on ‘Fibroblast Growth Factor Receptor 2 Inhibitor Market' - Global forecast to 2033
提及公司
同分類最新報告（醫療與生命科學）
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 Coherent Market Insights 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們